A Japanese health ministry panel will meet on June 29 to discuss whether to recommend approval for Janssen Pharmaceutical’s CAR-T cell therapy Carvykti (ciltacabtagene autoleucel) for earlier-line use in multiple myeloma. Carvykti is a B-cell maturation antigen (BCMA)-targeted CAR-T therapy…
To read the full story
Related Article
- Japan Panel OKs Carvykti’s Earlier Use in Multiple Myeloma
June 30, 2026
- Janssen’s CAR-T Therapy Carvykti Approved in Japan
September 27, 2022
REGULATORY
- CEA Review Group Debates Comparator Technologies, ICER Uncertainty
July 14, 2026
- Japan to Set Up Subgroup to Flesh Out Pharma Investment Roadmap: PM
July 13, 2026
- Immunization Act Revision Faces Uncertain Fate as Diet Clock Ticks Down
July 13, 2026
- MHLW Panel Examines Indication Mapping for OTC-Like Drug Charge Scheme
July 13, 2026
- Japan Targets Drug Discovery, Policing in Vertical AI Push
July 13, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…





